• Aminopeptidases 'do not have reported pharma benefits' for tauopathy
    The pharma benefits of PSA for tau clearance may not be supportable


Aminopeptidases 'do not have reported pharma benefits' for tauopathy

Nov 08 2010

Following reports of pharma effects on tauopathies - neurodegenerative disorders linked to the tau protein - using aminopeptidases, scientists at the University of Kentucky have found contrary evidence.

Writing in Molecular Neurodegeneration, they explain how they applied mass spectrometry and molecular sieve chromatography to determine whether the apparent pharma benefits in the previous reports could be supported experimentally.

The significance of their study arises from the aggregation of the tau protein in a number of degenerative conditions and the desire to understand more about clearing it in the brain.

However, when studying the cleavage reaction of tau to the puromycin sensitive aminopeptidase (PSA), the scientists were able to show that the results could occur independently of the PSA itself.

"It is concluded that PSA does not directly cleave tau," the team write in their research report.

Molecular Neurodegeneration disseminates research findings relating to cellular or molecular studies of degenerative neurological conditions.

Digital Edition

Chromatography Today - Buyers' Guide 2022

December 2021

In This Edition Modern & Practocal Applications - Accelerating ADC Development with Mass Spectrometry - Implementing High-Resolution Ion Mobility into Peptide Mapping Workflows Chromatogr...

View all digital editions


Lab Asia 2023

Oct 10 2023 Hybrid event

MicroTAS 2023

Oct 15 2023 Katowice, Poland

ISPPP 2023

Nov 05 2023 Vienna, Austria

SETAC North America

Nov 12 2023 Louisville, KY, USA

Eastern Analytical Symposium

Nov 13 2023 Plainsboro, NJ, USA

View all events